{"id":"aripiprazole-8-week-group","safety":{"commonSideEffects":[{"rate":"10-25","effect":"Akathisia"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Anxiety"},{"rate":"5-15","effect":"Insomnia"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing dopaminergic stabilization rather than pure antagonism. This mechanism reduces excessive dopamine signaling in hyperactive pathways while maintaining adequate dopamine function in hypoactive pathways. It also has activity at serotonin 5-HT1A and 5-HT7 receptors, contributing to its efficacy in treating schizophrenia, bipolar disorder, and depression.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:41.296Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Irritability associated with autism spectrum disorder"}]},"trialDetails":[{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT03423680","phase":"PHASE3","title":"A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","status":"RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-02-22","conditions":"Depression, Bipolar","enrollment":390},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT02955654","phase":"NA","title":"Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder","status":"WITHDRAWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT04765085","phase":"NA","title":"Clinical Efficacy and Change of Life Quality Through Using the Comprehensive Behavioral Intervention Treatment for Tics","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-03","conditions":"Tic Disorders","enrollment":""},{"nctId":"NCT03487783","phase":"PHASE3","title":"Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-05-02","conditions":"Tourette Syndrome","enrollment":121},{"nctId":"NCT03487770","phase":"PHASE3","title":"Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-04-09","conditions":"Autistic Disorder","enrollment":111},{"nctId":"NCT01696617","phase":"PHASE4","title":"Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-02-10","conditions":"Major Depressive Disorder","enrollment":46},{"nctId":"NCT01028820","phase":"PHASE4","title":"FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-08","conditions":"Autism Spectrum Disorder","enrollment":13},{"nctId":"NCT00337571","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Behavioral Symptoms, Autistic Disorder","enrollment":218},{"nctId":"NCT00332241","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Autistic Disorder","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify®"],"phase":"marketed","status":"active","brandName":"Aripiprazole 8-week group","genericName":"Aripiprazole 8-week group","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}